Subscribe
shutterstock_1364456177_madamf
madamF / Shutterstock.com
14 February 2022Americas

Split Fed Circuit refuses Teva 'skinny label' ruling review

A split US Court of Appeals for the Federal Circuit has declined to rehear a generic drug labelling dispute between Teva and GlaxoSmithKline.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Teva takes long-running ‘skinny label’ suit to SCOTUS
14 July 2022   Generics giant’s petition cites the cost of medicine and first-principles of innovation.
Generics
Teva asks Fed Circ for ‘skinny label’ redo
12 October 2021   Teva Pharmaceuticals has once again petitioned the US Court of Appeals for the Federal Circuit to reconsider its decision in a dispute over generic drug labelling which held that the drugmaker infringed GlaxoSmithKline’s Coreg heart drug.
Americas
Fed Circuit split over $235m skinny label verdict
10 August 2021   The US Court of Appeals for the Federal Circuit has reinstated a $235 million verdict against Teva in a split decision which could have major implications for skinny label generics.


Editor's picks

Patent attorneys by day, coders by night: Sterne Kessler launches ‘homemade’ AI assistant
Americas
Patent attorneys by day, coders by night: Sterne Kessler launches ‘homemade’ AI assistant
3 April 2025

Editor's picks

Americas
Patent attorneys by day, coders by night: Sterne Kessler launches ‘homemade’ AI assistant
3 April 2025
Americas
‘We need the top 50 law firms to stand up’: Will Perkins Coie ignite Trump resistance?
13 March 2025
Americas
Trouble at the USPTO—Part I: Why government cutbacks are making everyone nervous
6 March 2025
Americas
‘Lift as you climb’: Abbott, BMS, Hitachi, LEGO Group counsels explore ‘empowerment’
6 March 2025
Careers
Jones Day adds experienced patent litigators from Weil
4 March 2025
Americas
LSPN finalists revealed for first-ever US awards
3 March 2025

More on this story

Americas
Teva takes long-running ‘skinny label’ suit to SCOTUS
14 July 2022   Generics giant’s petition cites the cost of medicine and first-principles of innovation.
Generics
Teva asks Fed Circ for ‘skinny label’ redo
12 October 2021   Teva Pharmaceuticals has once again petitioned the US Court of Appeals for the Federal Circuit to reconsider its decision in a dispute over generic drug labelling which held that the drugmaker infringed GlaxoSmithKline’s Coreg heart drug.
Americas
Fed Circuit split over $235m skinny label verdict
10 August 2021   The US Court of Appeals for the Federal Circuit has reinstated a $235 million verdict against Teva in a split decision which could have major implications for skinny label generics.

More on this story

Americas
Teva takes long-running ‘skinny label’ suit to SCOTUS
14 July 2022   Generics giant’s petition cites the cost of medicine and first-principles of innovation.
Generics
Teva asks Fed Circ for ‘skinny label’ redo
12 October 2021   Teva Pharmaceuticals has once again petitioned the US Court of Appeals for the Federal Circuit to reconsider its decision in a dispute over generic drug labelling which held that the drugmaker infringed GlaxoSmithKline’s Coreg heart drug.
Americas
Fed Circuit split over $235m skinny label verdict
10 August 2021   The US Court of Appeals for the Federal Circuit has reinstated a $235 million verdict against Teva in a split decision which could have major implications for skinny label generics.

More features

Patent attorneys by day, coders by night: Sterne Kessler launches ‘homemade’ AI assistant
Mental health IP toolkit: Diversity Champ’s stress-busting tips
Eli Lilly piles on weight loss drug suits to ward off revenue squeeze
Patent cliff: 5 blockbusters running out of road
Herbert Smith Freehills expands German tech patent team
‘Always new twists’: Bayer legal team on defending a $4bn drug
Novartis and MSN feud intensifies after Fed Circ denies rehearing
EU court signals tough stance on ‘pay-for-delay’ pharma deals